文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

理解抗生素雾化吸入:肺微透析研究的关键作用

Understanding the nebulisation of antibiotics: the key role of lung microdialysis studies.
PubMed 文献 · Crit Care · 2024-02-19
一句话结论肺微透析可连续、区域性地测定肺组织间液中雾化抗生素浓度,有助于优化VAP雾化给药方案并推动诊疗一体化工具开发。

该综述指出,雾化抗生素是治疗多重耐药菌所致呼吸机相关性肺炎(VAP)有前景的方法,而确保感染部位组织间液中抗生素浓度达标对临床结局至关重要。现有上皮衬液和肺组织匀浆等评估方法难以提供纵向药代动力学数据。肺微透析主要用大型动物,将探针插入肺实质,测量组织间液中抗生素浓度,具有连续采样、区域评估和避免支气管污染等优势,但存在探针与检测开发成本高、需校准、对部分抗生素适用性有限等局限。该技术可研究药物种类、输送装置、呼吸机设置、接口和疾病状态等影响肺药代动力学的因素,结合体内药代动力学与体外药效学模拟可为雾化抗生素剂量优化提供依据,尤其可能帮助理解和优化多黏菌素雾化;并有望探索新型雾化疗法及监测肺炎中细胞因子、代谢物和炎症/感染标志物等动态生化变化,开发面向危重VAP患者的诊疗一体化工具。LUMINA(肺微透析应用于雾化抗生素)国际研究网络的建立,标志着向应对复杂性、促进未来多中心实验研究迈出的积极一步。

要点

  • 雾化抗生素是多重耐药菌所致VAP有前景的治疗方法,确保感染部位组织间液中有效抗生素浓度对临床结局至关重要。
  • 肺微透析主要用大型动物,将探针插入肺实质,连续测量组织间液中抗生素浓度,可区域评估肺内浓度并避免支气管污染。
  • 肺微透析的局限包括探针与检测开发成本、需探针校准、对某些抗生素适用性有限,且作为VAP研究工具需专科技术和资源密集型实验设计(大型动物长时间机械通气)。
  • 该技术可能帮助研究药物种类、输送装置、呼吸机设置、接口和疾病条件等影响肺药代动力学的因素,结合体内药代动力学与体外药效学模拟可为雾化抗生素剂量优化方案提供依据。
  • 该技术可能有助于理解和优化多黏菌素(对多重耐药革兰阴性菌有效)的雾化,并有望探索重定位抗生素制剂、噬菌体和免疫调节剂等新型雾化疗法。

适用人群与场景

  • 多重耐药菌所致呼吸机相关性肺炎(VAP)患者
  • 作为研究工具,肺微透析实验涉及接受长时间机械通气的大型动物

处置流程与药物剂量

  • 肺微透析通过将探针插入肺实质,测量组织间液中的抗生素浓度
  • 作为VAP研究工具,需专科技术和资源密集型实验设计,涉及大型动物长时间机械通气

研究设计与关键结果

  • 综述指出,上皮衬液和肺组织匀浆等现有评估方法在提供纵向药代动力学数据方面存在局限
  • 肺微透析具有连续采样、区域评估抗生素肺浓度、避免支气管污染等独特优势
  • 肺微透析的固有局限包括探针和检测开发成本、需探针校准、对某些抗生素适用性有限
  • 该技术可能使体内药代动力学与体外药效学模拟相结合,为雾化抗生素剂量优化方案提供见解
  • 该技术可能有助于理解和优化多黏菌素雾化,多黏菌素对多重耐药革兰阴性菌有效
  • 该技术有望探索新型雾化疗法,包括重定位抗生素制剂、噬菌体和免疫调节剂
  • 该技术有潜力监测肺炎中的动态生化变化,如细胞因子、代谢物和炎症/感染标志物,为开发面向危重VAP患者的诊疗一体化工具开辟途径
  • LUMINA(肺微透析应用于雾化抗生素)国际研究网络的建立,标志着向应对复杂性、促进未来多中心实验研究迈出的积极一步

证据类型、等级与局限

  • 证据类型:综述
  • 局限:原文未报告局限性

对床旁实践的改变

  • 作者认为,肺微透析可能成为变革性工具,实时洞察雾化抗生素药代动力学
  • 作者认为,肺微透析基于精确靶部位浓度告知最佳给药方案开发、促进诊疗一体化工具开发的潜力,使其成为推进多重耐药菌所致VAP治疗策略的关键角色

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Nebulisation of antibiotics is a promising treatment for ventilator-associated pneumonia (VAP) caused by multidrug-resistant organisms. Ensuring effective antibiotic concentrations at the site of infection in the interstitial space fluid is crucial for clinical outcomes. Current assessment methods, such as epithelial lining fluid and tissue homogenates, have limitations in providing longitudinal pharmacokinetic data.

MAIN BODY: Lung microdialysis, an invasive research technique predominantly used in animals, involves inserting probes into lung parenchyma to measure antibiotic concentrations in interstitial space fluid. Lung microdialysis offers unique advantages, such as continuous sampling, regional assessment of antibiotic lung concentrations and avoidance of bronchial contamination. However, it also has inherent limitations including the cost of probes and assay development, the need for probe calibration and limited applicability to certain antibiotics. As a research tool in VAP, lung microdialysis necessitates specialist techniques and resource-intensive experimental designs involving large animals undergoing prolonged mechanical ventilation. However, its potential impact on advancing our understanding of nebulised antibiotics for VAP is substantial. The technique may enable the investigation of various factors influencing antibiotic lung pharmacokinetics, including drug types, delivery devices, ventilator settings, interfaces and disease conditions. Combining in vivo pharmacokinetics with in vitro pharmacodynamic simulations can become feasible, providing insights to inform nebulised antibiotic dose optimisation regimens. Specifically, it may aid in understanding and optimising the nebulisation of polymyxins, effective against multidrug-resistant Gram-negative bacteria. Furthermore, lung microdialysis holds promise in exploring novel nebulisation therapies, including repurposed antibiotic formulations, bacteriophages and immunomodulators. The technique's potential to monitor dynamic biochemical changes in pneumonia, such as cytokines, metabolites and inflammation/infection markers, opens avenues for developing theranostic tools tailored to critically ill patients with VAP.

CONCLUSION: In summary, lung microdialysis can be a potential transformative tool, offering real-time insights into nebulised antibiotic pharmacokinetics. Its potential to inform optimal dosing regimen development based on precise target site concentrations and contribute to development of theranostic tools positions it as key player in advancing treatment strategies for VAP caused by multidrug-resistant organisms. The establishment of international research networks, exemplified by LUMINA (lung microdialysis applied to nebulised antibiotics), signifies a proactive step towards addressing complexities and promoting multicentre experimental studies in the future.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Dhanani J, Roberts JA, Monsel A, et al. Understanding the nebulisation of antibiotics: the key role of lung microdialysis studies. Crit Care. 2024. PMID: 38373973. doi:10.1186/s13054-024-04828-z

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。